VIVO

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Meridian Resubmits Application to FDA for Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay

Meridian Bioscience to Participate in the 41st Annual William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference

Meridian Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

Meridian Bioscience, Inc. (VIVO) CEO John Kenny on Q2 2021 Results - Earnings Call Transcript

Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021

Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-Ready™ LAMP Mix